The new drug in development, epratuzumab, was shown effective and well tolerated in a Phase 2 trial led by world-renowned lupus expert Dr. Daniel Wallace, member of the Board of Directors of our New York organization, the S.L.E. Lupus Foundation.
Results just published in the Annals of the Rheumatic Diseases reported on a randomized placebo-controlled multicenter study of patients with moderate to severe active lupus.
More: Patients with moderate to severe systemic lupus erythematosus experienced improvements in disease activity when assigned to a specific and well-tolerated dose of the CD22-targeted monoclonal antibody epratuzumab in a recent study. Treatment with a specific dose of the CD22-targeted monoclonal antibody epratuzumab improved disease activity and was well tolerated in patients with moderately to severely active SLE. Epratuzumab is currently in Phase 3 trials.